Guide contents
Open in calculatorCompound briefing
GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys complexed with Cu²⁺), first isolated from human plasma in 1973. Endogenous plasma levels decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — a decline correlated with reduced tissue-repair capacity. Transcriptome analysis shows GHK-Cu modulates expression of over 4,000 genes involved in tissue remodelling.
The research question
GHK-Cu sits at the intersection of copper chemistry and tissue signalling. Its research value lies in extracellular-matrix remodelling, wound models and changes in gene expression, with topical and systemic work requiring separate interpretation.
Mechanism & research themes
Acts as a biological signal of tissue damage — triggering stem cell activation, chemoattraction of repair cells, upregulation of collagen I/III/IV synthesis and broad transcriptome-level remodelling. Copper chelation also drives potent antioxidant activity via SOD stimulation.
Upregulated type I/III collagen synthesis with improved skin elasticity and density
Accelerated wound contraction, re-epithelialisation and angiogenesis
Increased follicle size and extended anagen phase in hair-growth studies
Reversal of aged-skin gene expression toward younger transcriptomic profiles
Potent free-radical scavenging via copper-mediated SOD activity
Emerging neuroprotection and lung-tissue repair signals in animal models
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Mechanistic, animal and dermatological studies provide a broad rationale, but study quality and formulation vary considerably. Gene-expression findings do not by themselves establish clinical outcomes.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Topical (most common): 1–5% peptide or cream, once or twice daily to target area. Injectable research protocols: 1–2mg subcutaneously or intradermally, 2–3× weekly to target area; systemic SC at 1–3mg/day. Cycles typically run 8–12 weeks.
Reported persistence
Plasma approximately 0.5–1 hour; tissue residence and biological effect persists for days to weeks.
Calculator starting point
2 mg per reference dose
3 doses per week · 10-week cycle
5 mL default reconstitution volume
Injectable research: 1–2 mg SC 2–3×/week, or 1–3 mg/day systemic.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate GHK-CuLaboratory handling
Reconstitution reference
Reconstitute a 50mg vial with 5mL bacteriostatic water for a 10mg/mL working concentration. The solution will appear blue-green — this is the copper complex and is expected.
Storage reference
Lyophilised: room temperature acceptable short-term; 2–8°C for long-term (stable 12–24 months). Reconstituted: 2–8°C, protect from direct light, use within 60 days. Blue-green colour does not indicate degradation.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Theoretical copper-accumulation risk at chronic high systemic doses — avoid in Wilson's disease or copper-metabolism disorders.
Mild transient redness or warmth at topical application sites, particularly at >5% concentrations.
In-vitro pro-oxidant activity has been observed at very high concentrations (>100µM) — well above therapeutic ranges, but relevant for high-dose injection protocols.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading